Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study
Therapeutic Advances in Medical Oncology
Published online on June 03, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival.Objectives:We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms ...
Background:Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival.Objectives:We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms ...